28-October-2026
Corporate News
 
Biocon signs Janssen deal to sell $6 bn Stelara Biosimilar in China, 8 other markets
26-Oct-2026

Biocon has signed a licence agreement with Janssen Sciences Ireland to commercialise Yesintek, its proposed biosimilar to Stelara, in nine additional markets. The company announced the deal in a statement to the exchanges. The agreement takes effect immediately. The statement did not disclose financial terms or a launch timeline.

News Source:- https://www.financialexpress.com/business/industry-biocon-signs-janssen-deal-to-sell-6-bn-stelara-biosimilar-in-china-8-other-markets-4369469/
 
 
 

Notes:
1. Copyright and ownership of all content from IMC and other IMC sites belongs to IMC except third-party resources
2. Copyright, intellectual property right, ownership or responsibility of error of other content belong to respective sources
3. Please do not reply to this mail

For suggestions and feedback click here.

Disclaimer:
IMC is not responsible for any kind of loss arising due to the information. You are receiving this newsletter because you have subscribed to this service. To unsubscribe click here.
Head Office : IMC Bldg., IMC Marg, Churchgate, Mumbai - 400 020 India  |   Tel : 91-22-22046633  |   Fax : 91-22-22048508 / 22838281
E-Mail : imc@imcnet.org  |   Website : www.imcnet.org